Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors

Inclusion Criteria:

1. Histologically confirmed solid tumor (leukemias and lymphomas excluded).
2. Malignancy that is incurable and for which standard (FDA approved or established standard clinical practice), curative, or palliative measures do not exist or are no longer effective.
3. ECOG performance status 2, 1 or 0.
4. Life expectancy greater than 6 months.
5. One or more measurable lesion(s) ("target lesion\[s\]"), that can be accurately measured in at least 1 dimension with longest diameter equal to or greater than 20 mm using conventional techniques (computed tomography \[CT\] scan or magnetic resonance imaging \[MRI\]) or equal to or greater than 10 mm with spiral CT scan.
6. If female, has a negative screening for pregnancy. Women of child-bearing potential and men must agree to use adequate contraception prior to study entry (hormonal or barrier method of birth control; abstinence) and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
7. Ability to understand the nature of the study and any hazards of participating in it, to communicate satisfactorily with the investigator, and to participate in, and comply with, the requirements of the entire study.
8. Willing to adhere to the prohibitions and restrictions specified in this protocol.
9. Patient must have signed an informed consent document.

Exclusion Criteria:

1. Recent major surgery (within the past 14 days).
2. Chemotherapy or dose of other potentially myelosuppressive treatment within 3 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin C).
3. Among patients with prior doxorubicin chemotherapy, only those with no more than a total cumulative dose of 450 mg/m2 of the drug.
4. Definitive radiotherapy (over 10 fractions and maximal area of hematopoietic active bone marrow treated was greater than 25%) within 4 weeks prior to entering the study.
5. Palliative radiotherapy (10 or less fractions) within 2 weeks prior to entering the study.
6. Residual adverse events (except alopecia, stable residual neuropathy, and residual hand, foot syndrome) and ascites requiring active medical management including paracentesis, peripheral bilateral edema, hyponatremia (serum value less than 130 Meq/L) due to previously administered agents, which have not recovered at grade 1 severity level or below before study entry.
7. Receiving any other investigational agents or concurrent chemotherapy, radiotherapy, hormonal treatments, bone marrow transplantation, or immunotherapy while on study. Exceptions are long-term hormonals for prostate (e.g. goserelin) and octreotide for neuroendocrine malignancies.
8. Previous bone marrow transplant.
9. Known brain metastases, except brain metastases that have been previously removed or irradiated and currently have no clinical impact.
10. History of allergic reactions attributed to compounds of similar chemical or biologic composition to ON 01910.Na.
11. Uncontrolled intercurrent illness.
12. Hgb less than 9 gm/dL (must not require transfusional support but erythropoietin therapy is permitted).
13. WBC less than 4,000/microliter.
14. Absolute neutrophil count less than 1,500/microliter.
15. Platelets less than or equal to 100,000/microliter.
16. Total bilirubin greater than 1.5 times institutional upper normal limit.
17. AST(SGOT)/ALT(SGPT) equal to or greater than 2.5 x institutional upper normal limit. (If liver function abnormalities are due to metastatic disease, patients are eligible provided the transaminases are \< 5 times institutional upper normal limit.).
18. Serum creatinine greater than 2 times upper limit of institutional normal value.
19. Pregnant and nursing women.
20. HIV-1 positive patients receiving combination anti-retroviral therapy.